Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
Companies Will Jointly Conduct Phase III Development and Commercialization of DGAT-1 Inhibitor Compounds
29-Aug-2007 -
Pfizer Inc and Bristol-Myers Squibb Company announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors. Pfizer's DGAT-1 discovery program includes advanced pre-clinical compounds with potential applications ...
Bayer
Bristol-Myers Squibb
fat storage
+4